Autopsy report · NCT04878484

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

“Poor recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Athenex, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

TCRT-ESO-A2

Participants

0

Trials that died the same way

• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (95% match in meaning)
• Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease
  “poor recruitment status” (93% match in meaning)
• Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
  “Inadequate recruitment” (92% match in meaning)
• Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents
  “Low recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.